Curanex Pharmaceuticals Inc

CURX

Business Summary

Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company focused on discovering, developing, and commercializing innovative botanical drugs to treat inflammatory diseases ¹. The company's mission is to address unmet medical needs by leveraging natural substances, specifically targeting immune and inflammatory conditions, as well as metabolic diseases and viral infections ². The global market for inflammatory disease treatments is experiencing rapid growth, driven by increasing prevalence, unmet medical needs, and limitations of existing therapies ³. The botanical and plant-derived drugs market, which includes pharmaceuticals, nutraceuticals, and herbal remedies, has expanded to approximately $34 billion USD ⁴, fueled by consumer preferences for natural and holistic health solutions ⁵.

Curanex's core business model is centered on the development and commercialization of botanical drug products, with its lead candidate, Phyto-N, currently in preclinical studies ⁶. The company anticipates future revenue primarily from product sales upon regulatory approval, strategic collaborations and licensing agreements that could provide upfront payments, milestone payments, and royalties, and potentially research grants and contracts ⁷. As of the date of the Annual Report, the company has not received any research grants or contracts ⁸.

The company's lead drug candidate, Phyto-N, is a proprietary botanical extract with potential anti-inflammatory properties derived from a medicinal plant with a 30-year history of human use in Chinese traditional medicine ⁹. Phyto-N has shown positive results in animal models of multiple inflammatory diseases ¹⁰. The current drug development pipeline encompasses six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (NAFLD), and gout ¹¹. Preclinical studies for Phyto-N have indicated potential anti-inflammatory, immunomodulatory, and tissue-protective properties in animal models across these indications ¹². The company previously conducted preclinical studies for acne treatment, but the results did not support further development, and a patent application for acne treatment was not pursued ¹³.

For the fiscal year ended December 31, 2025, Curanex reported no revenue from product sales ¹⁴. The company incurred a net loss of $4,225,106 ¹⁵, compared to a net loss of $361,506 ¹⁶ for the year ended December 31, 2024. General and administrative expenses increased to $1,253,203 ¹⁷ in 2025 from $290,386 ¹⁸ in 2024, primarily due to higher personnel-related expenses of approximately $623,000 ¹⁹ and increased professional fees associated with operating as a public company ²⁰. Research and development (R&D) expenses significantly rose to $2,985,873 ²¹ in 2025 from $74,676 ²² in 2024, driven by expanded IND-enabling studies and related research activities for its pipeline indications ²³. Interest expense was $8,537 ²⁴ in 2025, up from $nil ²⁵ in 2024, primarily from short-term promissory notes repaid in September 2025 ²⁶. Other income increased to $22,507 ²⁷ in 2025 from $3,554 ²⁸ in 2024, mainly due to higher interest income on increased cash balances following the IPO ²⁹. Basic and diluted net loss per common share was $(0.17) ³⁰ in 2025, compared to $(0.03) ³¹ in 2024.

The increase in net loss for 2025 was primarily due to the substantial rise in R&D expenses and general and administrative costs associated with the company's expanded development activities and public company operations ³². As of December 31, 2025, cash and cash equivalents stood at $4,973,134 ³³, a significant increase from $148,891 ³⁴ as of December 31, 2024, primarily due to net proceeds of approximately $15.3 million ³⁵ from the IPO and the over-allotment option exercise ³⁶. Net cash used in operating activities was $10,484,452 ³⁷ in 2025, up from $555,575 ³⁸ in 2024, reflecting increased operating expenses and a $6,253,298 ³⁹ increase in prepaid R&D expenses ⁴⁰. Net cash provided by financing activities was $15,308,695 ⁴¹ in 2025, compared to $630,100 ⁴² in 2024, driven by the IPO proceeds ⁴³.

During the reported period, Curanex completed its initial public offering (IPO) on August 27, 2025, with its common stock listed on The Nasdaq Capital Market under the symbol "CURX" ⁴⁴. The IPO generated gross proceeds of $15,000,000 ⁴⁵ from the sale of 3,750,000 shares ⁴⁶, and an additional $2,250,000 ⁴⁷ from the full exercise of the underwriters' over-allotment option for 562,500 shares ⁴⁸ on September 12, 2025 ⁴⁹. In February 2026, the company successfully completed a GMP pilot-scale batch of Phyto-N, intended to support IND-enabling nonclinical studies ⁵⁰. Key Chemistry, Manufacturing and Controls (CMC) activities completed include development of quality control methods, laboratory-scale process optimization, and scale-up and production of GMP-compliant pilot material ⁵¹. The company also completed a dose-range finding toxicology study in rats and dogs in March 2026, with no treatment-related adverse findings observed at any dose level ⁵². On June 17, 2024, Curanex acquired four provisional patent applications and eight research and development animal studies and reports from Duraviva Pharma Inc. for $730,000 ⁵³ and the issuance of 23,400,000 shares of common stock ⁵⁴. All four provisional patent applications expired on March 18, 2025, but the company filed an international PCT application on March 13, 2025, combining three of these applications to preserve priority dates and seek broader international protection ⁵⁵.

Business Outlook

Curanex Pharmaceuticals plans to submit an Investigational New Drug (IND) application for the treatment of ulcerative colitis in the fourth quarter of 2026 ⁵⁶. Subject to FDA allowance, a Phase I trial is planned to initiate 30 days post-IND submission ⁵⁷. If Phase I trials yield positive results, the company intends to proceed with a Phase II trial for ulcerative colitis as its lead indication ⁵⁸. Contingent on the success of ulcerative colitis trials, available funding, and other strategic considerations, Curanex may subsequently initiate additional Phase II trials in other high-value indications such as atopic dermatitis, COVID-19, gout, diabetes, and NAFLD, or may seek to license out these indications to third parties at the Phase II stage ⁵⁹.

The company's growth strategy is to leverage its expertise in botanical medicine to identify and develop novel drug candidates from herbal extracts and their active ingredients ⁶⁰. This approach aims to differentiate Curanex in the pharmaceutical industry and capitalize on the growing demand for natural treatment options ⁶¹. In addition to developing Phyto-N as a botanical drug, the company is actively identifying and isolating the active chemical compounds responsible for its therapeutic effects, with the potential to serve as the basis for novel small molecule drugs ⁶². This research is anticipated to conclude prior to the IND application filing for ulcerative colitis ⁶³. The global market for inflammatory bowel disease (IBD) treatment was valued at approximately $26.7 billion USD in 2023 ⁶⁴ and is projected to grow at a CAGR of 6-7% ⁶⁵ to reach $50 billion USD by the end of 2034 ⁶⁶. The global atopic dermatitis treatment market was valued at around $14.2 billion USD in 2022 ⁶⁷ and is expected to grow at a CAGR of 8-9% ⁶⁸ to reach $27.7 billion USD by the end of 2030 ⁶⁹. The global diabetes treatment market was valued at approximately $66 billion USD in 2023 ⁷⁰ and is projected to reach around $118 billion USD by 2032, growing at a CAGR of 6.67% ⁷¹. The NAFLD treatment market was valued at around $4.8 billion USD in 2022 ⁷² and is projected to reach $160 billion USD by the end of 2030, growing at a CAGR of approximately 55% ⁷³. The global gout treatment market size was valued at around $2.4 billion USD in 2022 ⁷⁴ and is projected to grow at a CAGR of 8.6% ⁷⁵ to reach $5.4 billion USD by the end of 2032 ⁷⁶.

Operationally, Curanex expects R&D expenses to remain significant as IND-enabling studies progress ⁷⁷. As of December 31, 2025, the company recorded approximately $6.2 million ⁷⁸ in prepaid R&D expenses, representing advance payments to CROs and CDMOs for services under ongoing IND-related studies ⁷⁹. The company is committed to investing in translational research to further elucidate Phyto-N's mechanisms of action, biomarkers, and patient stratification strategies to support a precision medicine approach and optimize clinical trial design ⁸⁰. The company plans to partner with experienced contract manufacturing organizations (CMOs) to ensure reliable and efficient production of botanical drug substances and products ⁸¹.

Curanex believes its existing cash and cash equivalents of $4,973,134 ⁸² as of December 31, 2025, will be sufficient to fund operating expenses and capital requirements for at least the next twelve months from the date of the Annual Report ⁸³. However, additional capital may be required for ongoing R&D and future clinical development programs, which the company may seek through equity or debt financings or other strategic arrangements ⁸⁴.

Management has explicitly flagged several structural headwinds and execution risks. The development and approval process for botanical drugs involves unique challenges, including the complex multi-component nature of botanical extracts, difficulties in standardization and quality control due to natural variations, challenges in predicting pharmacokinetics and drug interactions, potential intellectual property protection challenges, and manufacturing complexities in scaling up production ⁸⁵. With only four FDA-approved botanical drugs as of 2025 ⁸⁶, there is limited regulatory precedent, which may lead to a more complex and potentially longer regulatory review process, additional costs, and a higher risk of regulatory delays or rejections compared to conventional drug development ⁸⁷. The company also faces risks related to the highly competitive pharmaceutical industry, with major pharmaceutical, specialty pharmaceutical, and biotechnology companies having far greater marketing and research capabilities ⁸⁸.

Risk Factors

Curanex Pharmaceuticals faces substantial risks, including its limited operating history as a developmental stage company with no commercial products or revenue, requiring significant capital to execute its full business plan, estimated to be over $150 million USD ⁸⁹ through FDA approval and product launch, with no assurance of obtaining additional financing on acceptable terms or at all ⁹⁰. The company is heavily dependent on the success of its single lead product candidate, Phyto-N, and any failure in clinical trials or inability to obtain regulatory approval would significantly diminish its ability to sustain future operations ⁹¹. The development and approval process for botanical drugs presents unique challenges, such as the complex composition of extracts, difficulties in standardization and quality control, unpredictable pharmacokinetics and drug interactions, and manufacturing complexities, which may lead to additional costs, delays, or failure to obtain regulatory approval, as evidenced by only four FDA-approved botanical drugs to date ⁹². Intellectual property protection is also a significant risk, as the company's provisional patent applications expired on March 18, 2025, and there is no assurance that its international PCT application will result in successful registration of a utility patent in the United States or broader international protection ⁹³, potentially exposing the company to infringement claims and substantial litigation costs ⁹⁴. Furthermore, the company relies on third parties for manufacturing clinical drug supplies, exposing it to risks of delays, quality issues, and increased costs if these manufacturers fail to perform ⁹⁵. The company's management lacks prior experience as senior management of a public company, and fulfilling public company obligations will be expensive and time-consuming, potentially diverting attention from day-to-day operations ⁹⁶. The company also faces risks related to compliance with corporate governance laws and financial reporting standards, including identified material weaknesses in internal controls over financial reporting as of December 31, 2025 ⁹⁷, which could adversely impact public disclosures and stock price ⁹⁸. Geopolitical instability, including the ongoing war between Russia and Ukraine and conflicts in the Middle East, along with changes to U.S. tariff and import/export regulations and inflation, could disrupt operations, increase costs, reduce sales, and impair the ability to raise capital ⁹⁹. The company received a Nasdaq deficiency notice on November 5, 2025, for failing to meet the $1.00 per share minimum bid price requirement ¹⁰⁰, and there is no assurance it will regain compliance, potentially leading to delisting and adverse effects on stock liquidity and capital raising ability ¹⁰¹.

Management Priorities

Management's message to shareholders conveys a commitment to "Bringing hope and healing through the wisdom of plants" ¹⁰² by focusing on discovering, developing, and commercializing innovative botanical drugs for unmet medical needs, particularly inflammatory diseases ¹⁰³. They emphasize the strategic priority of advancing their lead product candidate, Phyto-N, which is currently in preclinical studies, towards clinical development ¹⁰⁴. Specifically, the company plans to submit an IND application for ulcerative colitis in the fourth quarter of 2026 ¹⁰⁵, with a Phase I trial to commence 30 days post-IND submission if allowed by the FDA ¹⁰⁶. A key strategic priority is to pursue a multiple indication strategy for Phyto-N, potentially initiating Phase II trials in other high-value indications such as atopic dermatitis, COVID-19, gout, diabetes, and NAFLD, or licensing these indications to third parties at the Phase II stage, contingent on the success of ulcerative colitis trials and available funding ¹⁰⁷. Management also highlights the ongoing investment in translational research to elucidate Phyto-N's mechanisms of action, biomarkers, and patient stratification strategies to support a precision medicine approach and optimize clinical trial design ¹⁰⁸.

View Source Annual Report on SEC.gov ↗

References

[1] Item 1, Description of Business — Overview
[2] Item 1, Description of Business — Overview
[3] Item 1, Description of Business — Opportunities and Challenges in the Pharmaceutical Industry for Botanical Drugs
[4] Item 1, Description of Business — Opportunities and Challenges in the Pharmaceutical Industry for Botanical Drugs
[5] Item 1, Description of Business — Opportunities and Challenges in the Pharmaceutical Industry for Botanical Drugs
[6] Item 7, MD&A — Our Business Model
[7] Item 7, MD&A — Our Business Model
[8] Item 7, MD&A — Our Business Model
[9] Item 1, Description of Business — Overview
[10] Item 1, Description of Business — Overview
[11] Item 1, Description of Business — Overview
[12] Item 1, Description of Business — Market Opportunities for Phyto-N
[13] Item 1, Description of Business — Product Pipelines
[14] Item 7, MD&A — Revenue and Cost of Sales
[15] Item 7, MD&A — Net Loss
[16] Item 7, MD&A — Net Loss
[17] Item 7, MD&A — General and Administrative Expenses
[18] Item 7, MD&A — General and Administrative Expenses
[19] Item 7, MD&A — General and Administrative Expenses
[20] Item 7, MD&A — General and Administrative Expenses
[21] Item 7, MD&A — Research and Development Expenses
[22] Item 7, MD&A — Research and Development Expenses
[23] Item 7, MD&A — Research and Development Expenses
[24] Item 7, MD&A — Interest Expense
[25] Item 7, MD&A — Interest Expense
[26] Item 7, MD&A — Interest Expense
[27] Item 7, MD&A — Other Income
[28] Item 7, MD&A — Other Income
[29] Item 7, MD&A — Other Income
[30] Item 8, Statements of Operations — Net Loss per Common Share: Basic and Diluted
[31] Item 8, Statements of Operations — Net Loss per Common Share: Basic and Diluted
[32] Item 7, MD&A — Net Loss
[33] Item 7, MD&A — Liquidity and Capital Resources
[34] Item 7, MD&A — Liquidity and Capital Resources
[35] Item 7, MD&A — Liquidity and Capital Resources
[36] Item 7, MD&A — Liquidity and Capital Resources
[37] Item 7, MD&A — Cash Flows from Operating Activities
[38] Item 7, MD&A — Cash Flows from Operating Activities
[39] Item 7, MD&A — Cash Flows from Operating Activities
[40] Item 7, MD&A — Cash Flows from Operating Activities
[41] Item 7, MD&A — Cash Flows from Financing Activities
[42] Item 7, MD&A — Cash Flows from Financing Activities
[43] Item 7, MD&A — Cash Flows from Financing Activities
[44] Item 1, Description of Business — Recent Developments
[45] Item 7, MD&A — Overview
[46] Item 7, MD&A — Overview
[47] Item 7, MD&A — Overview
[48] Item 7, MD&A — Overview
[49] Item 7, MD&A — Overview
[50] Item 1, Description of Business — GMP Pilot-Scale Manufacturing Milestone
[51] Item 1, Description of Business — GMP Pilot-Scale Manufacturing Milestone
[52] Item 1, Description of Business — Dose-Range Finding Toxicology Study
[53] Item 13, Certain Relationships and Related Transactions, and Director Independence — Asset Purchase Agreement
[54] Item 13, Certain Relationships and Related Transactions, and Director Independence — Asset Purchase Agreement
[55] Item 1, Description of Business — Intellectual Property
[56] Item 1, Description of Business — IND Submission Target and Clinical Development Plans
[57] Item 1, Description of Business — IND Submission Target and Clinical Development Plans
[58] Item 1, Description of Business — IND Submission Target and Clinical Development Plans
[59] Item 1, Description of Business — IND Submission Target and Clinical Development Plans
[60] Item 1, Description of Business — Our Growth Strategy
[61] Item 1, Description of Business — Our Growth Strategy
[62] Item 1, Description of Business — Our Growth Strategy
[63] Item 1, Description of Business — Our Growth Strategy
[64] Item 1, Description of Business — Market analysis of inflammatory bowel disease (IBD) treatment and the potential of Phyto-N
[65] Item 1, Description of Business — Market analysis of inflammatory bowel disease (IBD) treatment and the potential of Phyto-N
[66] Item 1, Description of Business — Market analysis of inflammatory bowel disease (IBD) treatment and the potential of Phyto-N
[67] Item 1, Description of Business — Market analysis of the Atopic Dermatitis (AD) treatment and the potential of Phyto-N
[68] Item 1, Description of Business — Market analysis of the Atopic Dermatitis (AD) treatment and the potential of Phyto-N
[69] Item 1, Description of Business — Market analysis of the Atopic Dermatitis (AD) treatment and the potential of Phyto-N
[70] Item 1, Description of Business — Market analysis for diabetes treatments and the potential of Phyto-N
[71] Item 1, Description of Business — Market analysis for diabetes treatments and the potential of Phyto-N
[72] Item 1, Description of Business — Market Analysis of Nonalcoholic Fatty Liver Disease (NAFLD) Treatments and the Potential of Phyto-N
[73] Item 1, Description of Business — Market Analysis of Nonalcoholic Fatty Liver Disease (NAFLD) Treatments and the Potential of Phyto-N
[74] Item 1, Description of Business — Market Analysis of Gout Treatments and Potential of Phyto-N
[75] Item 1, Description of Business — Market Analysis of Gout Treatments and Potential of Phyto-N
[76] Item 1, Description of Business — Market Analysis of Gout Treatments and Potential of Phyto-N
[77] Item 7, MD&A — Research and Development Expenses
[78] Item 7, MD&A — Research and Development Expenses
[79] Item 7, MD&A — Research and Development Expenses
[80] Item 1, Description of Business — Our Growth Strategy
[81] Item 1, Description of Business — Our Competitive Strengths
[82] Item 7, MD&A — Liquidity and Capital Resources
[83] Item 7, MD&A — Liquidity and Capital Resources
[84] Item 7, MD&A — Liquidity and Capital Resources
[85] Item 1, Description of Business — Botanical Drug Development Considerations
[86] Item 1, Description of Business — Botanical Drug Development Considerations
[87] Item 1, Description of Business — Botanical Drug Development Considerations
[88] Item 1, Description of Business — Competition
[89] Item 1A, Risk Factors — If we fail to raise capital when needed it will have a material adverse effect on our business, financial condition and results of operations.
[90] Item 1A, Risk Factors — If we fail to raise capital when needed it will have a material adverse effect on our business, financial condition and results of operations.
[91] Item 1A, Risk Factors — If we are unable to obtain patent protection for our lead product candidate, to successfully develop and commercialize Phyto-N, our ability to sustain future operations will be significantly diminished.
[92] Item 1A, Risk Factors — The development and approval process for botanical drugs involves unique challenges and regulatory considerations that may result in additional costs, delays, or failure to obtain regulatory approval.
[93] Item 1A, Risk Factors — If we are unable to obtain patent protection for our lead product candidate, to successfully develop and commercialize Phyto-N, our ability to sustain future operations will be significantly diminished.
[94] Item 1A, Risk Factors — Claims by other companies that we infringe on their proprietary technology may result in liability for damages or stop our development and commercialization efforts.
[95] Item 1A, Risk Factors — We will rely on third parties for the manufacturing of our clinical drug supplies, and we may face various risks and uncertainties based on our dependence on these manufacturers, which may impair the development of our drug candidates.
[96] Item 1A, Risk Factors — Our management does not have experience as senior management of a public company or ensuring compliance with public company obligations, and fulfilling these obligations will be expensive and time consuming, which may divert management’s attention from the day-to-day operation of its business.
[97] Item 9A, Controls and Procedures — Management’s Annual Report on Internal Control over Financial Reporting
[98] Item 1A, Risk Factors — Our failure to maintain effective internal controls over financial reporting could have an adverse impact on us.
[99] Item 1A, Risk Factors — Events such as natural disasters, industrial accidents, epidemics, pandemics, war and acts of terrorism, and adverse weather conditions could disrupt our business or the business of our customers, which could significantly harm our operations, financial results and cash flow.
[100] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Nasdaq Deficiency Notice
[101] Item 1A, Risk Factors — We may not be able to satisfy the listing requirements of Nasdaq to maintain a listing of our Common Stock.
[102] Item 7, MD&A — Overview
[103] Item 7, MD&A — Overview
[104] Item 7, MD&A — Overview
[105] Item 7, MD&A — Overview
[106] Item 7, MD&A — Overview
[107] Item 7, MD&A — Overview
[108] Item 7, MD&A — Our Business Model

Analysis on 5/22/2026